See analyst estimates and all valuation multiples for Pharmacies
Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
---|---|---|---|
$153B | 0.4x | 9.9x | |
$38.2B | 0.3x | 10.0x | |
$26.4B | 7.8x | 32.7x | |
$10.3B | 1.2x | 25.4x | |
$7.7B | 1.0x | 10.6x | |
$7.6B | 1.8x | 31.7x | |
$7.6B | 0.2x | 3.5x | |
$6.4B | 0.5x | 11.0x | |
$5.7B | 0.7x | 9.1x | |
$5.1B | 0.7x | 11.5x | |
$5.0B | 1.8x | 13.5x | |
$4.6B | 1.7x | 10.5x | |
$4.2B | 0.7x | 9.4x | |
$3.8B | 0.2x | 5.8x | |
$3.7B | 1.0x | 9.1x | |
$3.7B | 0.4x | 8.3x | |
$3.6B | 0.6x | 8.6x | |
$3.5B | 0.6x | 7.9x | |
$3.0B | 0.9x | 11.7x | |
$2.8B | 0.4x | 5.4x | |
$2.8B | 0.7x | 6.2x | |
$2.5B | 0.8x | 7.5x | |
$2.3B | 1.3x | 9.4x | |
$2.3B | 0.7x | 38.7x | |
$2.0B | 2.5x | 7.3x | |
$1.9B | 0.8x | 10.0x | |
$1.4B | 0.4x | 6.1x | |
$1.4B | 1.2x | 10.9x | |
$1.3B | 0.5x | 9.7x | |
$1.3B | 1.7x | 21.2x | |
$1.2B | n/a | n/a | |
$1.1B | n/a | n/a | |
$1.1B | n/a | n/a | |
$1.0B | 0.7x | 9.3x | |
$1.0B | 0.4x | 6.3x | |
$987M | n/a | n/a | |
$814M | n/a | n/a | |
$794M | 1.2x | 13.8x | |
$707M | 0.5x | -13.5x | |
$650M | n/a | n/a | |
$618M | n/a | n/a | |
$559M | 0.2x | 22.0x | |
$292M | 0.1x | n/a | |
$272M | n/a | n/a | |
$212M | 0.5x | 8.5x | |
$134M | n/a | n/a | |
$85.2M | n/a | n/a | |
$85.2M | 0.6x | 13.6x | |
$53.4M | n/a | n/a | |
$27.7M | n/a | n/a | |
$27.3M | 0.4x | 38.5x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Pharmacies